<DOC>
	<DOCNO>NCT02442466</DOCNO>
	<brief_summary>Intra-lesion administration Endothelin Receptor B inhibitor ( BQ-788 ) vehicle preform 5 melanoma patient preliminary analysis safety , dose , duration relevance result observe pre-clinical study human disease .</brief_summary>
	<brief_title>Proof Concept Study With Endothelin Receptor B Inhibitor ( BQ-788 ) Human Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>BQ 788</mesh_term>
	<criteria>Written Informed consent Histologically confirm melanoma Disease stage III IV At least 2 injectable surgically removable cutaneous metastasis Age &gt; 18 year Clinically stable medical condition Primary ocular melanoma Symptomatic intracranial melanoma History severe neurological , cardiovascular , renal , hepatic , endocrinological , respiratory , bone marrow , autoimmune infectious ( HIV ) disease Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>